- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Key statistics
As of last trade, Lexaria Bioscience Corp (LEXX:NAQ) traded at 2.81, 333.11% above the 52 week low of 0.6488 set on Jun 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.75 |
---|---|
High | 2.88 |
Low | 2.75 |
Bid | 2.81 |
Offer | 2.84 |
Previous close | 2.75 |
Average volume | 244.21k |
---|---|
Shares outstanding | 12.89m |
Free float | 11.24m |
P/E (TTM) | -- |
Market cap | 35.44m USD |
EPS (TTM) | -0.6851 USD |
Data delayed at least 15 minutes, as of May 23 2024 15:47 BST.
More ▼